Medical and Pharmaceutical

In the 257-person pivotal cohort, 42 per cent on 4 mg reached the scalp hair endpoint at Week 36, against 5 per cent on placebo.

The Swedish developer says the deal could bring up to €1.165B, but its published terms do not separate the upfront payment from later milestones.

The partners cited FDA discussions over Phase 2 evidence and kept a randomized Phase 3 lung cancer trial enrolling.

The small ALTITUDE follow-up lacks a control comparison; the dose is being tested in the sham-controlled NAAVIGATE trial.

Both doses passed a vision noninferiority test against ranibizumab; higher rates of retinal complications await detail.

The new Phase 3 study shifts its primary measure to lung function after an earlier miss, but aTyr says it needs more money to run it.

The FDA will decide whether to file the application for review after PROSERA's walking-distance gain missed its preset statistical cutoff.

The first US$7 million draw needs a shareholder vote, while later tranches depend on U.S. listing steps and the first Phase 3 site.

The TIBA test joins two existing checks on new commercial lots as Mesoblast scales U.S. sales of its pediatric cell therapy.

Advisers voted 10 to 0 on safety and 6 to 4 on effectiveness; the FDA has not set a date for its final decision.

Ricks gave no period or patient count for the estimate as Lilly broke ground on its US$6.5 billion Houston ingredients plant.

OASIZ 301 met its systemic disease measure, but Amgen did not disclose the treatment gap; a second Phase 3 study is due to finish this year.

The adult GEP-NET radiopharmaceutical is therapeutically equivalent to Lutathera, but Lantheus has not announced its launch date or price.

The 57-patient study missed its Week 12 skin disease endpoint, leaving five other autoimmune indications on Immunovant's development calendar.

Sefaxersen beat placebo on a week-37 urine protein measure, but Roche and Ionis have not disclosed the size of the effect or safety rates.

The Molecular and Clinical Genetics Panel votes Wednesday on whether the multi-cancer blood test is safe, effective and worth its risks.

A recent 1-for-10 reverse stock split hasn't had much of an impact

The firm now has 16 international patents for CyPath Lung

The devices measure carbon monoxide in a person's exhaled breath and report the results in parts per million

Results were revealed at this year's World Conference on Lung Cancer in Seoul

He believes efficacious drugs will be developed and tested at lightning speed

AI could consequently discover cancer treatments that researchers would not otherwise find during their lifetimes

Results of a study on this technique are intriguing but limited

The school has been continually strengthening its role in respiratory research

Lung cancer remains the leading cause of cancer death in the United States

A world-first approval breaking new ground in the cancer screening field

Non-small-cell lung cancer accounts for most lung cancer diagnoses

Angelman syndrome is a rare genetic nervous system disorder causing severe developmental delay

It is the only commercially available test of its kind

Artificial intelligence is making it easier to determine who needs a heart ultrasound most

Kardium makes an advanced heart disorder treatment device

A 30-day course of Rasonque costs US$39,800

Stock ascended by more than 150%

The findings could help researchers understand whether Aliya treatments can complement existing cancer immunotherapies

Rayence's latest and greatest mobile devices feature a proprietary new de-noising feature

SynCardia's Total Artificial Heart serves as a temporary solution while patients wait for donors

Many heavy smokers live into their senior years while others are taken far too young

Milestone follows the firm opening a California lab in April

Scribe instead wants one treatment to keep PCSK9 switched down for an extended period

It marks the first successful Phase 3 trial for an mRNA-based cancer therapy